VACCINE DEVELOPMENT FOR TUBERCULOSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 结核病（TB）仍然是全球健康负担，需要安全和新型疫苗策略。 使用非人灵长类动物的研究正在进行中，比较BCG与初免/加强疫苗接种策略，该策略使用BCG或设计成更具免疫原性的修饰BCG的初免，结合通过气溶胶递送的腺病毒载体的加强。 所有动物均已免疫接种，并通过支气管镜用500 CFU强毒TB（Erdman）攻击一个小亚组。 剩余动物将很快进行攻毒，攻毒后将对动物进行6个月随访。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Tuberculosis (TB) remains a global health burden for which safe and novel vaccine strategies are needed. Studies using nonhuman primates are underway comparing BCG to prime/boost vaccination strategies using a prime of either BCG or a modified BCG designed to be more immunogenic, combined with a boost of an adenoviral vector delivered via aerosol. All animals have been immunized and a small subgroup has been challenged via bronchoscope with 500CFU of virulent TB (Erdman). The remaining animals will be challenged soon and the animals will be followed for 6 months post challenge.